May 2026
Anxiety
What May 2026's 11 new studies found, synthesized from the papers below. All Anxiety research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.
Research in May 2026 indicates that psychedelic-assisted therapies, particularly psilocybin, show promise for reducing anxiety symptoms, with a systematic review reporting a large within-group effect (Hedge's g = 0.96) and a small between-group effect (Hedge's g = 0.48). However, results are mixed, as preclinical studies also report anxiogenic and null effects, and the evidence is limited by high heterogeneity in study designs and small sample sizes.
Confidence in the evidence
Low-Moderate- One systematic review and meta-analysis (article_id: 27866) with 25 studies provides pooled effect sizes, but high heterogeneity persists.
- Another systematic review (article_id: 29292) of 18 preclinical studies reports mixed effects (anxiolytic, anxiogenic, null), limiting consistency.
- Several studies are protocols, reviews, or qualitative (e.g., article_id: 27836, 27945), not providing direct quantitative evidence on anxiety outcomes.
- The narrative review (article_id: 28339) and editorial (article_id: 28020) offer general support but lack specific effect sizes or controlled data.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psicodélicos no tratamento de transtornos psiquiátricos: Evidências clínicas e desafios éticos 2026 | narrative review | Supports | Psychedelics like psilocybin, MDMA, and ayahuasca show promising results for anxiety when combined with supervised psychotherapy. | |
| Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis 2026 | systematic review and meta-analysis | 25 | Supports | Psilocybin-assisted psychotherapy produced a large within-group effect (Hedge's g = 0.96) and a small between-group effect (Hedge's g = 0.48) on anxiety symptoms, with high heterogeneity. |
| Serotonergic Psychedelics as a Potential Therapeutic Strategy for Anxiety, A Systematic Review 2026 | systematic review | 18 | Mixed | Serotonergic psychedelics showed anxiolytic-like effects in some tests, but anxiogenic and null effects were also reported. |
| Drugs for anxiety: from chloral hydrate to novel therapeutics 2026 | editorial | Supports | The editorial notes that psychedelic-assisted therapies are emerging as potential anxiolytic treatments, but highlights the need for improved medications. | |
| Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial. 2026 | study protocol | Unclear | This protocol describes a planned double-blind RCT of low-dose psilocybin with VR exposure therapy for social anxiety, but no results are reported. | |
| Anything that helps: cancer patient and carer perspectives on psychedelic-assisted therapy 2026 | qualitative | 15 | Supports | Cancer patients and carers expressed openness to psychedelic-assisted therapy for distress, provided risks are carefully managed. |
Psychedelics like psilocybin, MDMA, and ayahuasca show promising results for anxiety when combined with supervised psychotherapy.
narrative review
Psilocybin-assisted psychotherapy produced a large within-group effect (Hedge's g = 0.96) and a small between-group effect (Hedge's g = 0.48) on anxiety symptoms, with high heterogeneity.
systematic review and meta-analysis Sample size: 25
Serotonergic psychedelics showed anxiolytic-like effects in some tests, but anxiogenic and null effects were also reported.
systematic review Sample size: 18
The editorial notes that psychedelic-assisted therapies are emerging as potential anxiolytic treatments, but highlights the need for improved medications.
editorial
This protocol describes a planned double-blind RCT of low-dose psilocybin with VR exposure therapy for social anxiety, but no results are reported.
study protocol
Cancer patients and carers expressed openness to psychedelic-assisted therapy for distress, provided risks are carefully managed.
qualitative Sample size: 15
Points of agreement
- Psychedelic-assisted therapies, especially psilocybin, are considered promising for anxiety symptoms across multiple reviews.
- Combining psychedelics with psychotherapy is consistently highlighted as important for therapeutic benefit.
- There is a recognized need for better anxiety treatments due to limitations of current medications.
Conflicts
- Preclinical evidence (article_id: 29292) shows mixed effects (anxiolytic, anxiogenic, null), while clinical meta-analysis (article_id: 27866) shows a positive but heterogeneous effect.
- The narrative review (article_id: 28339) is broadly positive, but the editorial (article_id: 28020) emphasizes the need for improved medications, implying current options are insufficient.
Gaps
- Durability of anxiety reduction from psychedelic therapies is not addressed in the provided studies.
- Blinding and placebo control are challenging in psychedelic trials, and this is not discussed in detail.
- Specific populations (e.g., social anxiety, cancer-related anxiety) are understudied, with only protocols or qualitative data available.
- Dose-response relationships and optimal psychotherapy integration remain unclear.